Patents by Inventor Charles Michael Cook

Charles Michael Cook has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of antigen presentation by MHC class II molecules
    Patent number: 8598312
    Abstract: The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: December 3, 2013
    Assignee: Provid Pharmaceuticals, Inc.
    Inventors: Gary Lee Olson, Charles Michael Cook, Christopher Raymond Self
  • INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES
    Publication number: 20120252734
    Abstract: The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.
    Type: Application
    Filed: June 15, 2012
    Publication date: October 4, 2012
    Inventors: Gary Lee Olson, Charles Michael Cook, Christopher Raymond Self
  • Methods for the use of inhibitors of antigen presentation by MHC class II molecules
    Patent number: 8222215
    Abstract: The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: July 17, 2012
    Assignee: Provid Pharmaceuticals, Inc.
    Inventors: Gary Lee Olson, Charles Michael Cook, Christopher Raymond Self
  • Methionine aminopeptidase-2 inhibitors and methods of use thereof
    Publication number: 20090156624
    Abstract: The present invention provides methods of parasitic infections, thymoma, and lymphoid malignancies in a subject by administering to the subject a therapeutically effective amount of one or more of the compounds of the invention.
    Type: Application
    Filed: January 29, 2008
    Publication date: June 18, 2009
    Applicant: Praecis Pharmaceuticals Inc
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
  • METHODS FOR THE USE OF INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES
    Publication number: 20090111755
    Abstract: The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.
    Type: Application
    Filed: September 5, 2008
    Publication date: April 30, 2009
    Inventors: Gary Lee Olson, Charles Michael Cook, Christopher Raymond Self
  • Methionine aminopeptidase-2 inhibitors and methods of use thereof
    Patent number: 7105482
    Abstract: The present invention provides methods of treating, parasitic infections, thymoma, and lymphoid malignancies in a subject by administering to the subject a therapeutically effective amount of one or more of the compounds of the invention.
    Type: Grant
    Filed: May 2, 2003
    Date of Patent: September 12, 2006
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Patent number: 7084108
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Grant
    Filed: November 1, 2001
    Date of Patent: August 1, 2006
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Patent number: 7037890
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: May 2, 2006
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Patent number: 6919307
    Abstract: The present invention provides methods of treating a parasitic infection, a lymphoid malignancy or an autoimmune disorder in a subject by administering to the subject a therapeutically effective amount of an angiogenesis inhibitor compound comprising a MetAP-2 inhibitory core coupled to a peptide.
    Type: Grant
    Filed: May 2, 2002
    Date of Patent: July 19, 2005
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft
  • Inhibitors of antigen presentation by MHC class II molecules and methods of use thereof
    Publication number: 20040162242
    Abstract: The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.
    Type: Application
    Filed: February 13, 2004
    Publication date: August 19, 2004
    Inventors: Gary Lee Olson, Charles Michael Cook, Christopher Raymond Self
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Publication number: 20030109671
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Application
    Filed: May 2, 2002
    Publication date: June 12, 2003
    Applicant: Praecis Pharmaceuticals Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Patent number: 6548477
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Grant
    Filed: November 1, 2000
    Date of Patent: April 15, 2003
    Assignee: Praecis Pharmaceuticals Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens J. Birktoft
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Publication number: 20020193298
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Application
    Filed: October 5, 2001
    Publication date: December 19, 2002
    Applicant: Praecis Pharmaceuticals Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Publication number: 20020151493
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Application
    Filed: November 1, 2001
    Publication date: October 17, 2002
    Applicant: Praecis Pharmaceuticals Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel